NeoGenomics Dips Again as Earnings Optimism Fades

On FEB 4 2026, NeoGenomics (NEO) fell 2.32% in the last 24 hours to $12.5, marking continued downward momentum after a 6.7% drop over the last seven days. While the stock has recovered slightly with a 2.46% gain in the last month, it remains down 11.14% year-to-date, signaling ongoing investor caution.

Earnings Performance and Outlook

NeoGenomics delivered mixed quarterly earnings results in the last three reported quarters, showing some strong performances but missing expectations in key periods. In Q3 2025, the company beat earnings estimates with a $0.03 per share result, surpassing the $0.02 forecast, and reported revenue of $188 million, up 12% year-over-year. The stock surged 8.07% pre-market in response to the beat. However, recent data shows a less optimistic trend.

The upcoming Q4 2025 earnings are scheduled for February 17, 2026, with an estimated EPS forecast of $0.038 and revenue of $188.14 million. Analysts will be watching closely whether NeoGenomics can sustain its momentum in light of previous earnings misses in earlier quarters, including a surprise revenue shortfall in Q1 2025 and Q2 2025.

Guidance and Strategic Moves

The company maintains a full-year 2025 revenue guidance of $720 million to $726 million, projecting 9–10% growth. This guidance reflects confidence in its long-term strategy, including the rollout of the Radar ST assay in Q1 2026. NeoGenomics also highlighted strong growth in its Next-Generation Sequencing (NGS) segment, now accounting for 33% of clinical revenue, with a 24% year-over-year increase. Despite these strategic advances, the company faces challenges in expanding its Minimal Residual Disease (MRD) segment and integrating the newly acquired Pathline lab. These integration risks could weigh on short-term performance and investor sentiment.

Technical Indicators and Market Sentiment

Technical analysis on FEB 4, 2026, points to a bearish trend. The RSI stands at 51.78, suggesting a neutral position, while the Stochastic and Stochastic RSI indicators both signal a "Sell" position. The MACD indicator is in a "Buy" zone at 0.020, but other indicators such as ADX (29.28), ROC (-3.326), and CCI (-49.998) lean toward weakness.

Moving averages further reinforce this bearish bias, with a split between short-term and longer-term signals. The 5-day and 50-day EMA lines favor "Buy," while the 10-day and 20-day EMA lines, along with the 200-day EMA, remain in "Sell" or "Neutral" territory. Pivot points also suggest limited upside potential in the near term, with key support levels at 11.87 and 12.14.

Market Position and Financial Health

NeoGenomics continues to maintain a strong balance sheet, with liquid assets four times its short-term obligations. The company has also demonstrated a consistent ability to beat revenue expectations in several quarters. However, the recent earnings trend and weak technical indicators suggest that investors are pricing in uncertainty around the company's ability to sustain growth.

While the company has not announced any upcoming dividends, its focus on long-term growth and strategic investments in technology and lab capacity could provide a foundation for recovery. Investors remain cautious, weighing the company's strong fundamentals against near-term challenges in market execution and integration.

NEO Trend Chart